Edgar Filing: Retrophin, Inc. - Form 8-K

Retrophin, Inc. Form 8-K February 13, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 13, 2014

RETROPHIN, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-36257 27-4842691 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.)

777 Third Avenue, 22nd Floor, New York, NY
(Address of principal executive offices)
10017
(Zip Code)

Registrant's telephone number, including area code (646) 837-5863

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

CFR 240.13a-4(c))

Edgar Filing: Retrophin, Inc. - Form 8-K

Item 7.01. Regulation FD Disclosure.

On February 13, 2014, Retrophin, Inc. released a presentation on its corporate website in connection with its conference call discussing its agreement to acquire Manchester Pharmaceuticals LLC. The presentation is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Conference call presentation, dated February 13, 2014

Edgar Filing: Retrophin, Inc. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RETROPHIN, INC.

Date: February 13, 2014 By: /s/ Marc Panoff

Name: Marc Panoff

Title: Chief Financial Officer